Document Detail


How to avoid future Vioxx-type scandals.
MedLine Citation:
PMID:  15984108     Owner:  HSR     Status:  MEDLINE    
Abstract/OtherAbstract:
The market withdrawal of rofecoxib (Vioxx) in September 2004 was the logical, if long-overdue, result of what has become a major scandal. How can similar situations be avoided in the future? The authorities must of course come to grips with their responsibilities, but caregivers, patients and journalists also have a role to play. This was the theme of the press conference held at Prescrire headquarters after the annual awards ceremony on 20 January 2005
Authors:
-
Related Documents :
20446138 - Marketing in the long-term care continuum.
16395078 - Growth, development, and failure to thrive: factors that underlie the availability of p...
10165438 - Provider-sponsored hmos: make, buy, or joint venture?
9115458 - Home care in the older person.
24165218 - Toothbrushing versus toothbrushing plus tongue cleaning in reducing halitosis and tongu...
2407348 - Use of snail neurons in developing quantitative ultrastructural parameters for neurotox...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  14     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-28     Completed Date:  2005-07-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  France    
Other Details:
Languages:  eng     Pagination:  115-7     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / chemically induced*
Clinical Trials as Topic
Conflict of Interest
Disclosure
Drug Approval*
Drug Industry*
France
Government Regulation*
Humans
Journalism
Lactones / adverse effects*
Osteoarthritis / drug therapy
Product Surveillance, Postmarketing
Sulfones / adverse effects*
United States
United States Food and Drug Administration
Chemical
Reg. No./Substance:
0/Lactones; 0/Sulfones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
Next Document:  Waterhouse-Friderichsen cases in the archives of ZMS PAM--epidemiological conditions and diagnostic ...